The field of renal transplantation has progressed considerably in the past half-century largely due to an improved understanding of the role of the immune system in allograft rejection, the interpretation of the molecular mechanisms underlying graft failure, and better management of immunosuppression. However, due to the dynamic immune response of transplant patients, events such as acute rejection (AR) remains an obstacle occurring in approximately 15%–20% of patients using the current standard of care.
The current gold standard for detection of graft injury is an invasive biopsy following an increase in serum creatinine - both late indicators of injury:
- By the time creatinine levels elevate >50% of kidney function maybe lost. Creatinine levels are nothinghly specific or sensitive in the irreliability to detect clinically relevant events.
- Biopsies, the current gold standard for assessing graft status, are invasive, painful, inconvenient and unsuited for serial monitoring. Biopsies yield in conclusive results as often as 30% of the time.
Immune activation can lead to chronic graft injury and requires cost-intensive care, reduce the quality of life of patients, and may ultimately result in total graft loss.
A non-invasive Molecular Blood Assay is now available for the detection and surveillance of kidney allograft status to identify successful rejection treatment.
We offers this assay though a CLIA certified, CAP accredited service Laboratory in the United States.
Only blood sample is required - collected in special container (to be provided upon request) and the results will be available within 72 hours of receiving the sample at the reference lab.
